From Tier Table Database
CDC Office of Public Health Genomics (OPHG) conducts horizon scanning (a systematic research method to find and follow novel technologies appearing in the literature) to identify and track the progress of genomic tests as they move from research into clinical and public health practice. As an aid in organizing horizon scanning results, OPHG ranks genomic tests, and family health history applications, by levels of evidence. See detail.
| Disease/Disorder | Test to be Assessed | Intended Use | Tier Classified | Detail |
|---|---|---|---|---|
| Dukes’ C colon cancer, metastatic colorectal cancer, metastatic breast cancer | DPD testing | Pharmacogenomic for 5-FU (capecitabine) | Tier 2  | |
| Risk for primary breast cancer or breast cancer recurrence | CYP2D6 | Pharmacogenomic - informing therapeutic choice, tamoxifen | Tier 2 | |
| Invasive breast cancer and breast cancer | ER-alpha and PgR status | Pharmacogenomic: for ER-alpha (ESR1)-modulating agents, recurrence risk, prognostic | Tier 2 | |
| Breast cancer | Gene expression profiles | Recurrence: risk prediction; prognostic | Tier 2 | |
| Breast cancer (ER+/LN-/HER2-), intermediate risk of recurrence | Oncotype DX® | prognostic; guiding decision-making: adjuvant chemotherapy | Tier 1 |
.png)
No hay comentarios:
Publicar un comentario